RAZELLE KURZROCK, MD
Medical College of Wisconsin · Moores Cancer Center at University of California at San Diego · Medical College of Wisconsin, Milwaukee, WI, USA
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name RAZELLE KURZROCK, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:43 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07754292 · Off-Label Treatment With Immune Checkpoint Inhibitor BlockadeMedical College of Wisconsin · not yet recruiting · Malignancy · principal investigator
- N/ANCT06228599 · Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer RecurrenceMedical College of Wisconsin · recruiting · Pancreas Cancer · principal investigator
- N/ANCT05802069 · MCW Master Predict (Profile Related Evidence Determining Individualized Cancer Therapy)Sameem M. Abedin, MD · recruiting · Cancer · principal investigator
- Ph1/Ph2NCT05674825 · Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor PrognosesMedical College of Wisconsin · recruiting · Cancer · principal investigator
- N/ANCT04028479 · The Registry of Oncology Outcomes Associated With Testing and TreatmentTaproot Health · completed · Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer · study chair
- Ph1/Ph2NCT03386929 · Survival Prolongation by Rationale Innovative GenomicsWorldwide Innovative Network Association · terminated · Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB · principal investigator
- N/ANCT02534675 · Study of Molecular Profile-Related Evidence to Determine Individualized Therapy for Advanced or Poor Prognosis CancersUniversity of California, San Diego · completed · Cancer · principal investigator
- Ph1NCT00520637 · A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)Enzon Pharmaceuticals, Inc. · completed · Advanced Solid Tumors, Lymphoma · principal investigator
- Ph1NCT00509782 · Phase I Trial of ZIO-101 in Patients With Solid TumorsM.D. Anderson Cancer Center · completed · Solid Tumors · principal investigator
- Ph1NCT00496444 · Azacytidine and Valproic Acid in Patients With Advanced CancersM.D. Anderson Cancer Center · completed · Advanced Cancers · principal investigator
- Ph1NCT00430014 · Study of Atiprimod Treatment for Patients With Advanced CancerM.D. Anderson Cancer Center · terminated · Advanced Cancer · principal investigator
- Ph2NCT00003048 · Amifostine in Treating Patients With Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Myelodysplastic Syndromes · study chair
- Ph2NCT00038376 · Phase II Study Of Roferon and Accutane For Patients With T-Cell MalignanciesM.D. Anderson Cancer Center · completed · Lymphoma, T-Cell, Mycosis Fungoides, Hematologic Neoplasms · principal investigator
- Ph2NCT00038025 · A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid MalignanciesM.D. Anderson Cancer Center · completed · Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Chronic Lymphocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:43 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT00003048
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.